SEC Form 4 · accession 0001638599-16-000929
CorMedix Inc. · CRMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Duffy
Director
Period of report
May 24, 2016
Accepted (ET)
May 26, 2016 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001410098
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value per shareF1 | May 24, 2016 | X | 21,454 | $0.40 | A | 74,677 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to purchase Common Stock)F6 | $0.40 | May 24, 2016 | X | 25,000 | D | Nov 13, 2012 | Nov 13, 2017 | Common Stock, $0.001 par value per share | 25,000 | 0 | D |
| Phantom StockF9,F8 | $0.00 | May 13, 2016 | A | 1,153 | A | — | — | Common Stock, $0.001 par value per share | 1,153 | 1,153 | D |
| Stock Option (right to buy)F2 | $2.02 | holding | — | — | — | — | Jan 9, 2024 | Common Stock, $0.001 par value per share | 150,000 | 150,000 | D |
| Stock Option (right to buy)F3 | $2.02 | holding | — | — | — | — | Jan 9, 2024 | Common Stock, $0.001 par value per share | 30,000 | 30,000 | D |
| Stock Option (right to buy)F4 | $0.90 | holding | — | — | — | — | Mar 20, 2023 | Common Stock, $0.001 par value per share | 100,000 | 100,000 | D |
| Stock Option (right to buy)F5 | $0.68 | holding | — | — | — | — | Dec 5, 2022 | Common Stock, $0.001 par value per share | 125,000 | 125,000 | D |
| Stock Option (right to buy)F3 | $0.29 | holding | — | — | — | — | Jan 6, 2022 | Common Stock, $0.001 par value per share | 5,000 | 5,000 | D |
| Stock Option (right to buy)F7 | $0.28 | holding | — | — | — | — | Nov 21, 2021 | Common Stock, $0.001 par value per share | 15,000 | 15,000 | D |
| Stock Option (right to buy)F3 | $5.62 | holding | — | — | — | — | Mar 1, 2025 | Common Stock, $0.001 par value per share | 50,000 | 50,000 | D |
| Phantom StockF8 | $0.00 | holding | — | — | — | — | — | Common Stock, $0.001 par value per share | 594 | 594 | D |
| Stock Option (right to buy)F3 | $1.91 | holding | — | — | — | — | Feb 21, 2026 | Common Stock, $0.001 par value per share | 75,000 | 75,000 | D |
| Phantom StockF8 | $0.00 | holding | — | — | — | — | — | Common Stock, $0.001 par value per share | 1,653 | 1,653 | D |
Explanation of responses
- F1Does not represent a sale in the market; represents the cashless exercise through the forfeiture of shares to the Issuer to pay the purchase price of the shares acquired upon conversion of the warrant.
- F2These options vested 100% on January 10, 2014.
- F3These options vest in full on the first anniversary of the date of grant.
- F4These options vest quarterly over two years.
- F5These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- F6On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
- F7The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- F8Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo
- F9These shares were credited automatically to the reporting person's account pursuant to the reporting person's election to defer the receipt of cash compensation of director's fees.